AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.35 |
Market Cap | 27.79M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.77 |
PE Ratio (ttm) | -0.48 |
Forward PE | n/a |
Analyst | Buy |
Ask | 0.38 |
Volume | 665,243 |
Avg. Volume (20D) | 1,864,060 |
Open | 0.30 |
Previous Close | 0.31 |
Day's Range | 0.29 - 0.38 |
52-Week Range | 0.13 - 2.45 |
Beta | undefined |
About TOI
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants ser...
Analyst Forecast
According to 1 analyst ratings, the average rating for TOI stock is "Buy." The 12-month stock price forecast is $2.5, which is an increase of 579.72% from the latest price.
Next Earnings Release
Analysts project revenue of $109.15M, reflecting a 27.23% YoY growth and earnings per share of -0.07, making a -66.67% decrease YoY.
2 months ago · seekingalpha.com
The Oncology Institute, Inc. (TOI) Q3 2024 Earnings Call TranscriptThe Oncology Institute, Inc. (NASDAQ:TOI ) Q3 2024 Earnings Conference Call November 13, 2024 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO Rob Carter - CF...